Advertisement

New Insights Into The Regulation Of Dopamine Receptor Subtypes And Their Roles In Behavior

  • Ian Creese
Chapter

Abstract

Previous research has demonstrated the existence of two distinct dopamine receptor subtypes (Kebabian & Calne, 1979; Creese et al. 1983), possessing unique pharmacologic and biochemical properties. D1 dopamine receptors stimulate adenylate cyclase activity, while D2 dopamine receptors inhibit this enzyme and may well have other second messenger systems. However both receptor subtypes co-exist in many tissues making the determination of their respective physiological and behavioral roles difficult. All neuroleptics, commonly used drugs in the treatment of schizophrenia, have been shown to be either mixed D1/D2 receptor antagonists or selective D2 receptor antagonists. These drugs, when administered to animals, induce profound motoric effects, termed catalepsy, which are characterized by the inability to initiate movement. This drug-induced behavioral syndrome is similar to some of the symptoms of Parkinson’s disease. Indeed, when administered to man, a similar spectrum of “extrapyramidal motor effects” are induced — which are ameliorated by anti-par-kinsonian drugs such as anticholinergics. Thus the behavioral effects of neuroleptics mimic some of the symptoms of Parkinson’s disease which are probably mediated by identical underlying biochemical substrates. D2 receptors have been implicated as the site mediating both the antipsychotic and the antidopaminergic, extrapyramidal motoric effects of neuroleptics (Creese et al., 1976; Seeman et al., 1976). By inference, D2 receptors have been considered to be the mediators of dopaminergic agonists’ behavioral effects. These behavioral effects are also motoric — agonists such as L-DOPA, apomorphine or amphetamine stimulating motor activity at low doses, while dyskinesias and stereotyped motor responses occur at higher doses in both animals and man. However, all of these agonists activate both D2 and D1 receptors.

Keywords

Dopamine Receptor Dopamine Agonist Dopamine Receptor Subtype Receptor Upregulation Receptor Selective Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arnt, J. Behavioural studies of dopamine receptors; evidence for regional selectivity and receptor multiplicity. In Dopamine Receptors, edited by I. Creese and C. Fraser, A.R. Liss, pp 199–232, 1987Google Scholar
  2. Braun, A.R., Barone, R and Chase, T.N. Interaction of D1 and D2 receptors in the expression of dopamine agonist induced behaviors. In Neurobiology of Central D1-Dopamine Receptors, I. Creese and G.R. Breese, eds., pp 151–166, Plenum Press, New York, (1986)Google Scholar
  3. Breese, G.R. and Mueller, R.A. SCH-23390 Antagonism of a D-2 dopamine agonist depends upon catecholaminergic neurons. Eur. J. Pharmacol. 113:109–114, 1985PubMedCrossRefGoogle Scholar
  4. Burt, D.R., Creese, I. and Snyder, S.H. Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain. Science 196:326–328, (1977)PubMedCrossRefGoogle Scholar
  5. Carlson, J.H., Bergstrom, D.A. and Walters, J.R. Stimulation of both Dl and D2 dopamine receptors appears necessary for full expression of postsynaptic effects of dopamine agonists: A neurophysiological study. Brain Res. 400:205–216, 1987PubMedCrossRefGoogle Scholar
  6. Christensen, A.V., Arnt, J. Hyttel, J., Larsen, J.J. and O. Pharmacological effects of a specific dopamine D-l antagonist SCH 23390 in comparison with neuroleptics. Life Sci. 34:1529–1540, 1984PubMedCrossRefGoogle Scholar
  7. Creese, I. and Chen, A. Selective D-l dopamine receptor increase following chronic treatment with SCH 23390. Eur. J. Pharmacol. 109:127–128, 1985PubMedCrossRefGoogle Scholar
  8. Creese, I. and Sibley, D.R. Receptor adaptations to centrally acting drugs. Ann. Rev. Pharmacol. Toxicol. 21:357–391(1980)CrossRefGoogle Scholar
  9. Creese, I., Burt, D.R. and Snyder, S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 192:481–483, 1976PubMedCrossRefGoogle Scholar
  10. Creese, I. and Iversen, S.D. The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Res. 83:419–436, 1975PubMedCrossRefGoogle Scholar
  11. Creese, I., Sibley, D.R., Hamblin, M.W. and Leff, S. The classification of dopamine receptors: relationship to radioligand binding. Ann. Rev. Neurosci. 6:43–71, 1983PubMedCrossRefGoogle Scholar
  12. Ezrin-Waters, C. and Seeman, P. Tolerance to haloperidol catalepsy. Eur. J. Pharmacol. 41:321–327, 1977PubMedCrossRefGoogle Scholar
  13. Fleminger, S., Rupniak N.M.J., Hall, M.D., Jenner, P. and Marsden, C.A. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-l receptors. Biochem. Pharmacol. 32:2921–2927, 1983PubMedCrossRefGoogle Scholar
  14. Hess, E.J., Albert, L.J., Le, H. and Creese, I. Effects of chronic SCH 23390 treatment of the biochemical and behavioral properties of D1 and D2 dopamine receptors: Potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation. J. Pharmacol. Exp. Ther. 238:846–854 (1986)PubMedGoogle Scholar
  15. Hess, E.J., Norman, A.B. and Creese, I. Chronic treatment with dopaine receptor antagonists: behavioral and pharmacologic effects of D1 and D2 dopamine receptors. J. Neuroscience, in press, 1988Google Scholar
  16. Iorio, L.C., Barnett, A., Leitz, F.H. Houser, V.P. and Korduba, C.A. SCH 23390, a potential benzazepine antipsychotic with unique interactions of dopaminergic systems. J. Pharm. Exp. Ther. 226:462–468,1983Google Scholar
  17. Itoh, Y., Goldman, M.E. and Kebabian, J.W. TL333, a benzhydro[G]quinoline, stimulates both D-l and D-2 dopamine receptors: Implications for the selectivity of LY 141865 towards the D-2 receptor. Eur. J. Pharmacol. 108:99–101, 1985PubMedCrossRefGoogle Scholar
  18. Kebabian, J.W. and Calne, D.B. Multiple receptors for dopamine. Nature. 277:93–96, 1979PubMedCrossRefGoogle Scholar
  19. Mailman, R.B., Schulz, D.W., Lewis, M.H., Staples, L., Rollema, H. and Dehaven, D.L. SCH 23390: A selective D1 dopamine antagonist with potent D2 behavioral actions. Eur. J. Pharmacol. 101:159–160,1984PubMedCrossRefGoogle Scholar
  20. Meller, E., Bohmaker, K. Goldstein, M. and Freidhoff, A.J. Inactivation of D1 and D2 dopamine receptors by N-ethoxycarbonyl-2-ethoxy-l,2-dihydroquinoline in vivo: Selective protection by neuroleptics. J. Pharmacol. and Exp. Ther. 233:656–6621, 1985aGoogle Scholar
  21. Meller, E., Kuga, S., Freidhoff, A.J. and Goldstein, M. Selective D2 dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D1 antagonist. Life Sci. 36:1857–18641, 1985bPubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Ian Creese
    • 1
  1. 1.Rutgers State University of New JerseyNewarkUSA

Personalised recommendations